Free Trial
→ No. 1 stock to cash in on the death of iPhone (From Stansberry Research) (Ad)tc pixel
NASDAQ:DTIL

Precision BioSciences Q3 2026 Earnings Date & Estimates

Precision BioSciences logo
$6.72 +0.29 (+4.51%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$6.71 -0.01 (-0.15%)
As of 10/9/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Precision BioSciences is expected to report Q3 2026 earnings on Monday, November 2, 2026, before market opens. The conference call is scheduled for November 6, 2026 at 9:30 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call Date
Conference Call
9:30 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Precision BioSciences in Q3 2026

Precision BioSciences is expected to post earnings of -$0.85 per share on revenue of $1.38 million. In the same quarter a year earlier Precision BioSciences reported -$1.84 per share on revenue of $0.01 million. Precision BioSciences last reported on August 6, 2026, posting -$1.26 per share and missing the -$0.8040 consensus estimate. Precision BioSciences has beaten the consensus EPS estimate in 2 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.85
Expected Revenue
$1.38 million
Prior-Year EPS
-$1.84
Prior-Year Revenue
$0.01 million
Expected Revenue Growth
+10,476.9%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$1.26 (Missed by -$0.4560)
EPS Beat Rate
2 of last 8 quarters

Prepare for the Q3 2026 Call

Precision BioSciences Q3 2026 Earnings FAQ

Precision BioSciences (NASDAQ:DTIL) is estimated to report Q3 2026 earnings on Monday, November 2, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Precision BioSciences' Q3 2026 earnings conference call is scheduled for Friday, November 6, 2026 at 9:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Precision BioSciences to post earnings of -$0.85 per share for Q3 2026.

The consensus revenue estimate for Precision BioSciences is $1.38 million for Q3 2026.

Precision BioSciences Earnings Headlines

Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting 2026
October 8 at 7:01 AM  |  businesswire.comhttps://www.businesswire.com/news/home/20261008153055/en/precision-biosciences-announces-late-breaking-oral-presentation-for-pbgene-hbv-at-aasld-the-liver-meeting-2026/
Precision BioSciences (NASDAQ:DTIL) Stock: Insider Geno Germano Purchases 2,609 Shares
October 1, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31073288
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.tc pixel
October 10 at 1:00 AM  |  Chaikin Analytics (Ad)
Analysts Offer Insights on Healthcare Companies: Hinge Health, Inc. Class A (HNGE) and Precision BioSciences (DTIL)
September 30, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/HNGE/pressreleases/4848441/analysts-offer-insights-on-healthcare-companies-hinge-health-inc-class-a-hnge-and-precision-biosciences-dtil/
Precision Biosciences Inc.
September 23, 2026  |  barrons.comhttps://www.barrons.com/market-data/stocks/dtil/company-people?gaa_sig=MwOfBC_uyS_qI-lAabkKUUgxCmYxqNk85vBjJHDfEveGuobjHltFDlnp6slddq20nmtga9uenZ89XkIm6lfxjw%3D%3D
Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study
August 24, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260824221319/en/precision-biosciences-commences-dosing-in-phase-12-function-dmd-study/
See More Precision BioSciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Precision BioSciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Precision BioSciences and other key companies, straight to your email.

About Precision BioSciences

Precision BioSciences (NASDAQ:DTIL) is a biotechnology company developing gene-editing therapies for serious diseases. The company’s work is based primarily on its proprietary ARCUS platform, which uses engineered nucleases designed to make precise changes to DNA inside the body.

Precision BioSciences is focused on in vivo gene editing programs addressing conditions including chronic hepatitis B, Duchenne muscular dystrophy and alpha-1 antitrypsin deficiency. Its development efforts are intended to remove, insert or repair genetic material and potentially provide durable treatments after a single administration.

Founded in 2006 and headquartered in Durham, North Carolina, the company has also pursued cell therapy programs and strategic collaborations to apply its gene-editing technology to additional therapeutic areas. Precision BioSciences serves global biopharmaceutical and healthcare markets through its research, development and partnership activities.

View Precision BioSciences Profile
Earnings Tools